No Data
No Data
Chinese Health: 2024 Annual Report Summary
Chinese Health: 2024 Annual Report
Express News | Chinese Health: The net income in 2024 is 0.138 billion yuan, a year-on-year increase of 20.09%
Express News | China Health: Shareholder Saifu Investment, holding over 5% shareholding, plans to reduce its shareholding by no more than 1.5%.
China Health (301408.SZ): Not involved in the production, sales, and related industrial layout of exoskeleton Siasun Robot&Automation.
On April 9th, Gelonghui reported that Huaren Health (301408.SZ) stated on its investor interaction platform that the company focuses on the pharmaceutical health sector and has not engaged in the production, sales, or related industrial layout of exoskeleton robots. In the future, we will continue to pay attention to emerging technologies and market dynamics within the Industry, actively exploring opportunities that align with the company's Global Strategy.
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.